Page results
-
UCLH is contributing to a national priority trial of the drug ruxolitinib in patients with Covid-19 pneumonia (infection of the lungs).
-
Advice on preventing the spread of flu and other respiratory viruses, to keep UCLH patients safe.
-
This page tells you about the procedure known as varicocele (pronounced VARI-CO-SEAL) embolisation.
-
A major new consortium led by UCLH and UCL has been awarded £6.8 million by the National Institute of Health Research to conduct the largest clinical study of long COVID over the next two years.
-
A study of patients at UCLH and North Middlesex University Hospital published in The Lancet Infectious Diseases suggests that the B.1.17. variant of Covid-19 is not associated with more severe illness and death, but appears to lead to higher virus load.
-
Pfizer Limited, in agreement with the Medicines Healthcare products Regulatory Agency (MHRA), has withdrawn the product, while a review of the benefits and risks is carried out.
-
The hospital marked the start of the year a visit by HM The Queen in February 2020. A few weeks after this celebration, the pandemic took hold and the hospital stepped up to help.
-
Specialist teams at UCLH and UCL are at the forefront of research which could bring hope to people who have been robbed of their sense of smell and taste after suffering the long-term legacy of COVID-19.
-
Bed availability is a “significant” factor in determining whether or not a patient is admitted to a critical care bed after surgery, questioning whether some are getting the care they need, a new study from researchers at UCL and UCLH has found for the first time.
-
UCLH NHS Foundation Trust has once again formed a partnership with the Business Design Centre in Islington to reopen a large-scale COVID-19 vaccination centre on site from Saturday 18 December.
File results
-
FOI/2024/0162 - Various technology systems/ services used at Trust
-
FOI/2024/0163 - Renal cell carcinoma and melanoma treatments
-
FOI/2024/0166 - Recruitment systems/CRM platform
-
FOI/2024/0171 - Dermatology consultants
-
FOI/2024/0172 - Patients excluded from care at the Trust 2010-2023
-
FOI/2024/0179 - Water usage/ procurement
-
FOI/2024/0183 - Immunology Hidradenitis Suppurativa (HS) treatment
-
FOI/2024/0184 - IT spend/ Healthcare Information and Management Systems Society (HIMSS) EMRAM and INFRAM scores
-
FOI/2024/0190 - Scheduled appointments Did Not Attend (DNA) 2019-2023
-
FOI/2024/0192 - Net zero and decarbonisation targets